STOCK TITAN

Cidara Therapeutics to Participate in the World Antiviral Congress 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Cidara Therapeutics (NASDAQ: CDTX) announced that its President and CEO, Jeff Stein, Ph.D., will join a panel at the World Antiviral Congress in San Diego, California, from November 28 to December 1, 2022.

The discussion will focus on pandemic preparedness and developing broad-spectrum therapeutics. The panel session titled 'Therapeutic Approaches to Pandemic Preparedness' is scheduled for December 1, 2022, from 8:20 to 9:30 a.m. PST at Loews Coronado Bay Resort. Cidara is innovating long-acting therapeutics, targeting serious diseases, including its lead Phase 3 antifungal candidate, rezafungin.

Positive
  • None.
Negative
  • None.

SAN DIEGO, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeff Stein, Ph.D., President and CEO, will participate in a panel discussion at the World Antiviral Congress being held in San Diego, California from November 28-December 1, 2022.

The panel will discuss pandemic preparedness and therapeutic approaches, including predictions on the next viral threat, development of broad-spectrum drugs and platforms to engineer novel therapeutics.

Panel Details:

Title: Therapeutic approaches to pandemic preparedness
Location: Loews Coronado Bay Resort, San Diego, CA, Congress Room 4
Session Date/Time: December 1, 2022, at 8:20 – 9:30 a.m. PST

To register and view the full congress schedule, visit the World Antiviral Congress’ website here.

About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to DFCs targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

MEDIA CONTACT:
Patrick Bursey
LifeSci Communications
(203) 430-9545
pbursey@lifescicomms.com


FAQ

What is the focus of CDTX's panel discussion at the World Antiviral Congress?

The panel discussion will focus on pandemic preparedness and therapeutic approaches, including the development of broad-spectrum drugs.

When is the panel session featuring CDTX's CEO scheduled?

The panel session is scheduled for December 1, 2022, from 8:20 to 9:30 a.m. PST.

Where will the World Antiviral Congress be held?

The World Antiviral Congress will be held at Loews Coronado Bay Resort in San Diego, California.

What is CDTX's lead candidate being discussed in the panel?

CDTX's lead candidate is rezafungin, which is in Phase 3 clinical trials as an antifungal treatment.

How can I register for the World Antiviral Congress?

You can register and view the full congress schedule on the World Antiviral Congress' website.

Cidara Therapeutics, Inc.

NASDAQ:CDTX

CDTX Rankings

CDTX Latest News

CDTX Stock Data

252.14M
10.85M
4.73%
51.86%
0.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO